Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |
PMID | |
Authors | MA. Shah, K Shitara, F Lordick, Yung-Jue Bang, Niall C. Tebbutt, Jean-Philippe Metges, Kei Muro, Lin Shen, Sergei Tjulandin, John L. Hays, Rui-hua Xu, Marilyn Fontaine, Emily Brooks, Bo Xu, Wei Li, Chiang Li, Laura Borodyansky, Eric Van Cutsem |
Title | The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. |
Journal | Journal of Clinical Oncology |
Vol | |
Issue | |
Date | |
URL | http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.4010 |
Abstract Text | Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 4010-4010 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | gastric adenocarcinoma | not applicable | Napabucasin + Paclitaxel | Phase III | Actionable | In a Phase III (BRIGHTER) trial, combination of Napabucasin (BBI608) and Taxol (paclitaxel) did not significantly improve overall survival (6.93 vs 7.36 months, HR=1.01, p=0.8596) or progression-free survival (3.55 vs 3.65 months, HR=1.00, p=0.9679) compared to placebo in patients with pretreated, advanced gastric and gastroesophageal junction adenocarcinoma (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 4010-4010; NCT02178956). | detail... |
Unknown unknown | gastroesophageal junction adenocarcinoma | not applicable | Napabucasin + Paclitaxel | Phase III | Actionable | In a Phase III (BRIGHTER) trial, combination of Napabucasin (BBI608) and Taxol (paclitaxel) did not significantly improve overall survival (6.93 vs 7.36 months, HR=1.01, p=0.8596) or progression-free survival (3.55 vs 3.65 months, HR=1.00, p=0.9679) compared to placebo in patients with pretreated, advanced gastric and gastroesophageal junction adenocarcinoma (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 4010-4010; NCT02178956). | detail... |